Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors

Area of Science:

• Oncology
• Immunotherapy
• Urothelial Carcinoma

Background:

• Immune checkpoint inhibitors (ICIs) have transformed metastatic urothelial cancer treatment.
• Durvalumab and tremelimumab are established ICI therapies.
• Management of exceptional responders requires careful consideration.

Observation:

• A patient with metastatic upper tract urothelial cancer achieved a complete response to durvalumab and tremelimumab.
• Following treatment, the patient developed multiple non-invasive papillary bladder tumors.
• Next-generation sequencing was performed on both primary and secondary tumors.

Findings:

• The bladder tumors were found to share ancestry with the original upper tract urothelial cancer.
• Key genetic differences were identified between the upper tract and bladder tumors.
• Notably, a TP53 missense mutation present in the upper tract disease was absent in the bladder tumors.

Implications:

• This case highlights the evolving landscape of urothelial cancer management with ICIs.
• Understanding tumor evolution in exceptional responders is crucial.
• Genetic profiling can inform clinical decision-making in complex cases.